These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33425028)

  • 1. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.
    Xu H; Xu X; Ge W; Lei J; Cao D
    Ther Adv Med Oncol; 2020; 12():1758835920980546. PubMed ID: 33425028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
    Fan Y; Xie W; Huang H; Wang Y; Li G; Geng Y; Hao Y; Zhang Z
    Front Oncol; 2021; 11():633032. PubMed ID: 33912454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis.
    Wang D; Chen C; Gu Y; Lu W; Zhan P; Liu H; Lv T; Song Y; Zhang F
    Front Oncol; 2021; 11():631949. PubMed ID: 33732650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liang Y; Xu H; Liu F; Li L; Lin C; Zhang Y; Wang N; Wang L
    Front Oncol; 2024; 14():1281645. PubMed ID: 38887231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
    Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
    Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Petrelli F; Grizzi G; Ghidini M; Ghidini A; Ratti M; Panni S; Cabiddu M; Ghilardi M; Borgonovo K; Parati MC; Tomasello G; Barni S; Berruti A; Brighenti M
    J Immunother; 2020 Jan; 43(1):1-7. PubMed ID: 31574022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ma S; Nie H; Wei C; Jin C; Wang L
    Front Oncol; 2024; 14():1402017. PubMed ID: 38779082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
    Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
    Front Oncol; 2021; 11():704475. PubMed ID: 34631533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
    Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; PĂ©ron J
    Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
    Ng KYY; Tan SH; Tan JJE; Tay DSH; Lee AWX; Ang AJS; Wong LWJ; Choo SP; Tai DW; Lee JJX
    Liver Cancer; 2022 Jan; 11(1):9-21. PubMed ID: 35222504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis.
    Li S; Wang T; Lai W; Zhang M; Cheng B; Wang S; Tong G
    Transl Cancer Res; 2021 Dec; 10(12):5150-5158. PubMed ID: 35116365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Chen J; Liu H; Dai J; Zhao J; Zhu S; Zhang X; Liang J; Hu X; Zhao J; Liu Z; Shen P; Sun G; Zeng H
    Cancer Treat Rev; 2024 Jun; 129():102787. PubMed ID: 38905806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis.
    Lin L; Liu Y; Chen C; Wei A; Li W
    Front Pharmacol; 2023; 14():1190001. PubMed ID: 37284302
    [No Abstract]   [Full Text] [Related]  

  • 20. Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors.
    Zhang YC; Zhu TC; Nie RC; Lu LH; Xiang ZC; Xie D; Luo RZ; Cai MY
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.